Our proof of concept for the targeting of the TRPV6 calcium channel in prostate cancer is based on the generation of rabbit polyclonal antibodies capable of recognizing and binding to the extracellular epitopes of the channel, such as the first extracellular loop between S1 and S2 for rb79 and the pore region for rb82. Here, TRPV6 is linked to prostate cancer.